2023
Towards precision medicine for anxiety disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs
Roseberry K, Le-Niculescu H, Levey D, Bhagar R, Soe K, Rogers J, Palkowitz S, Pina N, Anastasiadis W, Gill S, Kurian S, Shekhar A, Niculescu A. Towards precision medicine for anxiety disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. Molecular Psychiatry 2023, 28: 2894-2912. PMID: 36878964, PMCID: PMC10615756, DOI: 10.1038/s41380-023-01998-0.Peer-Reviewed Original ResearchConceptsIndependent cohortCandidate biomarkersPsychiatric subjectsPersonalized approachConvergent functional genomics approachAnxiety disordersBest overall evidenceAdverse life eventsClinical worseningGene expression signaturesBlood biomarkersAnxiety medicationClinical utilityPsychiatric disordersHigh anxiety stateSevere anxietyUntreated anxietyDecrease qualityIndividual biomarkersAddiction potentialBiomarkersTop biomarkersAnxiety statesRisk predictionExpression signatures
2012
Prevalence of Takotsubo cardiomyopathy in the United States
Deshmukh A, Kumar G, Pant S, Rihal C, Murugiah K, Mehta JL. Prevalence of Takotsubo cardiomyopathy in the United States. American Heart Journal 2012, 164: 66-71.e1. PMID: 22795284, DOI: 10.1016/j.ahj.2012.03.020.Peer-Reviewed Original ResearchConceptsTakotsubo cardiomyopathyHigher oddsAlcohol abuseNationwide Inpatient Sample databaseHistory of smokingAnxiety statesGeneral US populationTimes higher oddsNinth RevisionClinical syndromePeak incidenceHospitalization recordsElderly womenInternational ClassificationUS populationHospitalizationDischarge recordsSample databaseAge-gender interactionPrevalenceWomenTakotsuboHyperlipidemiaSmokingCardiomyopathy
2003
Longitudinal Trajectories of Depression and Anxiety in a Prospective Community Study: The Zurich Cohort Study
Merikangas KR, Zhang H, Avenevoli S, Acharyya S, Neuenschwander M, Angst J. Longitudinal Trajectories of Depression and Anxiety in a Prospective Community Study: The Zurich Cohort Study. JAMA Psychiatry 2003, 60: 993-1000. PMID: 14557144, DOI: 10.1001/archpsyc.60.9.993.Peer-Reviewed Original ResearchConceptsComorbid anxietyDiagnostic thresholdZurich cohort studyLong-term followCommunity-based cohortMajor mental disordersProspective community studyCommunity-based sampleCohort studyProspective studyComorbid statesAffective disordersMental disordersDiagnostic InterviewMid adulthoodCanton of ZurichCommunity studyAnxiety statesSubthreshold levelsAssessment pointsDepressionDisordersLongitudinal trajectoriesTreatment researchAnxiety
1992
Dose-response relationship for oral idazoxan effects in healthy human subjects: comparison with oral yohimbine
Krystal J, McDougle C, Woods S, Price L, Heninger G, Charney D. Dose-response relationship for oral idazoxan effects in healthy human subjects: comparison with oral yohimbine. Psychopharmacology 1992, 108: 313-319. PMID: 1355923, DOI: 10.1007/bf02245117.Peer-Reviewed Original ResearchConceptsHealthy subjectsDiastolic blood pressureΑ2-adrenergic receptorsSymptom scale scoresHealthy human subjectsDose-response relationshipIdazoxan doseBlood pressureOral yohimbineNorepinephrine metabolitePlasma levelsMedication effectsOral administrationPlasma MHPGPhysiologic indicesNeuroendocrine responsesΑ2 antagonistAdrenergic receptorsCortisol levelsScale scorePlasma cortisolYohimbineIdazoxanAnxiety statesReceptor specificity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply